Anti-NMDA-R autoinmune encephalitis in times of COVID-19

Descripción del Articulo

A 19-year-old woman who started with respiratory symptoms and later presented subacute symptoms with behavioral and neurological disorder associated with hallucinations, aggressiveness, mutism, epileptic seizures, facial dyskinesias and fever. MRI was normal, EEG recorded delta waves, CSF and serum...

Descripción completa

Detalles Bibliográficos
Autores: Bazalar, Giuliana, Azañero-Haro, Johan, Piscoya, Tatiana, Chambi, Liliana, Soto, Alonso
Formato: artículo
Fecha de Publicación:2023
Institución:Sociedad Peruana de Medicina Interna
Repositorio:Revista de la Sociedad Peruana de Medicina Interna
Lenguaje:español
OAI Identifier:oai:medicinainterna.net.pe:article/724
Enlace del recurso:https://revistamedicinainterna.net/index.php/spmi/article/view/724
Nivel de acceso:acceso abierto
Materia:Encefalitis
Autoinmuinidad
Encefalitis por anticuerpos antirreceptor
N-Metil-D-Aspartato
COVID-19
Encephalitis
Autoimmunity
Encephalitis due to N-methyl-D-aspartate receptor antibodies
id REVSPMI_2f5606c49db76511c338c3925ea44195
oai_identifier_str oai:medicinainterna.net.pe:article/724
network_acronym_str REVSPMI
network_name_str Revista de la Sociedad Peruana de Medicina Interna
repository_id_str
spelling Anti-NMDA-R autoinmune encephalitis in times of COVID-19Encefalitis autoinmune por anticuerpos NMDA-R en tiempos del COVID-19Bazalar, GiulianaAzañero-Haro, Johan Piscoya, Tatiana Chambi, Liliana Soto, AlonsoEncefalitisAutoinmuinidadEncefalitis por anticuerpos antirreceptorN-Metil-D-AspartatoCOVID-19EncephalitisAutoimmunityEncephalitis due to N-methyl-D-aspartate receptor antibodiesCOVID-19A 19-year-old woman who started with respiratory symptoms and later presented subacute symptoms with behavioral and neurological disorder associated with hallucinations, aggressiveness, mutism, epileptic seizures, facial dyskinesias and fever. MRI was normal, EEG recorded delta waves, CSF and serum studies were negative for secondary causes. Treatment was initiated with acyclovir, anticonvulsants and, subsequently, she received methylprednisolone with immunoglobulin without satisfactory response. Treatment with rituximab was started, with a favorable response. The CSF panel was positive for NMDAr. It is important to recognize early the neuropsychiatric manifestations of this pathology for an opportune management having a positive impact on the long term prognosis.Mujer de 19 años que inició con cuadro respiratorio y posteriormente presentó cuadro subagudo con trastorno conductual y neurológico asociado a alucinaciones, agresividad, mutismo, crisis epilépticas, discinesias faciales y fiebre. La resonancia fue normal, el EEG registró ondas delta, los estudios de LCR y séricos fueron negativos para causas secundarias. Se inició tratamiento con aciclovir, anticonvulsivantes y, posteriormente, recibió metilprednisolonacon inmunoglobulina sin respuesta satisfactoria. Se inició tratamiento con rituximab presentando una respuesta favorable. El panel en LCR fue positivo a NMDAr. Es importante reconocer tempranamente las manifestaciones neuropsiquiátricas de esta patología para un manejo oportuno teniendo un impacto positivo en el pronóstico a largo plazo.Sociedad Peruana de Medicina Interna2023-02-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistamedicinainterna.net/index.php/spmi/article/view/72410.36393/spmi.v36i1.724Revista de la Sociedad Peruana de Medicina Interna; Vol. 36 Núm. 1 (2023); e724Revista de la Sociedad Peruana de Medicina Interna; Vol. 36 No. 1 (2023); e7241609-71731681-972110.36393/spmi.v36i1reponame:Revista de la Sociedad Peruana de Medicina Internainstname:Sociedad Peruana de Medicina Internainstacron:SPMIspahttps://revistamedicinainterna.net/index.php/spmi/article/view/724/793Derechos de autor 2023 Giuliana Bazalar, Johan Azañero-Haro, Tatiana Piscoya, Liliana Chambi, Alonso Sotoinfo:eu-repo/semantics/openAccessoai:medicinainterna.net.pe:article/7242023-05-07T20:24:07Z
dc.title.none.fl_str_mv Anti-NMDA-R autoinmune encephalitis in times of COVID-19
Encefalitis autoinmune por anticuerpos NMDA-R en tiempos del COVID-19
title Anti-NMDA-R autoinmune encephalitis in times of COVID-19
spellingShingle Anti-NMDA-R autoinmune encephalitis in times of COVID-19
Bazalar, Giuliana
Encefalitis
Autoinmuinidad
Encefalitis por anticuerpos antirreceptor
N-Metil-D-Aspartato
COVID-19
Encephalitis
Autoimmunity
Encephalitis due to N-methyl-D-aspartate receptor antibodies
COVID-19
title_short Anti-NMDA-R autoinmune encephalitis in times of COVID-19
title_full Anti-NMDA-R autoinmune encephalitis in times of COVID-19
title_fullStr Anti-NMDA-R autoinmune encephalitis in times of COVID-19
title_full_unstemmed Anti-NMDA-R autoinmune encephalitis in times of COVID-19
title_sort Anti-NMDA-R autoinmune encephalitis in times of COVID-19
dc.creator.none.fl_str_mv Bazalar, Giuliana
Azañero-Haro, Johan
Piscoya, Tatiana
Chambi, Liliana
Soto, Alonso
author Bazalar, Giuliana
author_facet Bazalar, Giuliana
Azañero-Haro, Johan
Piscoya, Tatiana
Chambi, Liliana
Soto, Alonso
author_role author
author2 Azañero-Haro, Johan
Piscoya, Tatiana
Chambi, Liliana
Soto, Alonso
author2_role author
author
author
author
dc.subject.none.fl_str_mv Encefalitis
Autoinmuinidad
Encefalitis por anticuerpos antirreceptor
N-Metil-D-Aspartato
COVID-19
Encephalitis
Autoimmunity
Encephalitis due to N-methyl-D-aspartate receptor antibodies
COVID-19
topic Encefalitis
Autoinmuinidad
Encefalitis por anticuerpos antirreceptor
N-Metil-D-Aspartato
COVID-19
Encephalitis
Autoimmunity
Encephalitis due to N-methyl-D-aspartate receptor antibodies
COVID-19
description A 19-year-old woman who started with respiratory symptoms and later presented subacute symptoms with behavioral and neurological disorder associated with hallucinations, aggressiveness, mutism, epileptic seizures, facial dyskinesias and fever. MRI was normal, EEG recorded delta waves, CSF and serum studies were negative for secondary causes. Treatment was initiated with acyclovir, anticonvulsants and, subsequently, she received methylprednisolone with immunoglobulin without satisfactory response. Treatment with rituximab was started, with a favorable response. The CSF panel was positive for NMDAr. It is important to recognize early the neuropsychiatric manifestations of this pathology for an opportune management having a positive impact on the long term prognosis.
publishDate 2023
dc.date.none.fl_str_mv 2023-02-18
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistamedicinainterna.net/index.php/spmi/article/view/724
10.36393/spmi.v36i1.724
url https://revistamedicinainterna.net/index.php/spmi/article/view/724
identifier_str_mv 10.36393/spmi.v36i1.724
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistamedicinainterna.net/index.php/spmi/article/view/724/793
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedad Peruana de Medicina Interna
publisher.none.fl_str_mv Sociedad Peruana de Medicina Interna
dc.source.none.fl_str_mv Revista de la Sociedad Peruana de Medicina Interna; Vol. 36 Núm. 1 (2023); e724
Revista de la Sociedad Peruana de Medicina Interna; Vol. 36 No. 1 (2023); e724
1609-7173
1681-9721
10.36393/spmi.v36i1
reponame:Revista de la Sociedad Peruana de Medicina Interna
instname:Sociedad Peruana de Medicina Interna
instacron:SPMI
instname_str Sociedad Peruana de Medicina Interna
instacron_str SPMI
institution SPMI
reponame_str Revista de la Sociedad Peruana de Medicina Interna
collection Revista de la Sociedad Peruana de Medicina Interna
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1845705333025013760
score 12.773366
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).